Mineralocorticoid receptor antagonists have been shown to reduce mortality in patients after myocardial infarction with congestive heart failure. Whether routine use of spironolactone is ...

Explore how cortisol’s dual role in the brain influences mental health, with pioneering research by Dr. Ron de Kloet driving ...

SGLT2 inhibitors plus finerenone may have a protective effect against cardiovascular events in patients with HFpEF or HFmrEF.

A review article emphasizes optimizing GDMT and getting early referrals to better manage risks and weigh benefits.

Esaxerenone is a selective, potent, and long-lasting nonsteroidal mineralocorticoid receptor antagonist developed on the ...

In this randomized controlled trial of patients with heart failure and mildly decreased or preserved ejection fraction, ...

However, there was a suggestion that the mineralocorticoid receptor antagonist may reduce new or worsening heart failure. And although the trial had a high rate of study-drug discontinuation ...

Spironolactone is a mineralocorticoid receptor antagonist medication that blocks certain hormones. The study was a randomized, double-blind, placebo-controlled clinical trial (meaning participants ...